Compare Stocks: INKT, FTFT, GLSI, and KROS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FTFT Future FinTech Group	$0.92 -10.2%	$2.76	$0.84 ▼ $62.08	$1.71M	1.89	49,421 shs	98,035 shs
GLSI Greenwich LifeSciences	$13.35 -1.1%	$20.79	$7.78 ▼ $34.10	$195.45M	1.4	242,223 shs	34,958 shs
INKT MiNK Therapeutics	$10.65 +1.4%	$11.45	$8.48 ▼ $18.17	$53.02M	0.48	141,945 shs	1,519 shs
KROS Keros Therapeutics	$10.01 -0.6%	$10.70	$9.69 ▼ $22.55	$197.92M	0.97	347,475 shs	32,702 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FTFT Future FinTech Group	0.00%	-13.56%	-58.20%	-83.55%	-96.84%
GLSI Greenwich LifeSciences	0.00%	+4.01%	-38.64%	-43.04%	+21.73%
INKT MiNK Therapeutics	0.00%	-5.15%	-10.03%	-9.56%	-28.67%
KROS Keros Therapeutics	0.00%	+0.10%	-10.57%	-12.36%	-29.68%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FTFT Future FinTech Group	$0.92 -10.2%	$2.76	$0.84 ▼ $62.08	$1.71M	1.89	49,421 shs	98,035 shs
GLSI Greenwich LifeSciences	$13.35 -1.1%	$20.79	$7.78 ▼ $34.10	$195.45M	1.4	242,223 shs	34,958 shs
INKT MiNK Therapeutics	$10.65 +1.4%	$11.45	$8.48 ▼ $18.17	$53.02M	0.48	141,945 shs	1,519 shs
KROS Keros Therapeutics	$10.01 -0.6%	$10.70	$9.69 ▼ $22.55	$197.92M	0.97	347,475 shs	32,702 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FTFT Future FinTech Group	0.00%	-13.56%	-58.20%	-83.55%	-96.84%
GLSI Greenwich LifeSciences	0.00%	+4.01%	-38.64%	-43.04%	+21.73%
INKT MiNK Therapeutics	0.00%	-5.15%	-10.03%	-9.56%	-28.67%
KROS Keros Therapeutics	0.00%	+0.10%	-10.57%	-12.36%	-29.68%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FTFT Future FinTech Group	1.00	Sell	N/A	N/A
GLSI Greenwich LifeSciences	2.33	Hold	$57.00	326.97% Upside
INKT MiNK Therapeutics	2.67	Moderate Buy	$35.00	228.73% Upside
KROS Keros Therapeutics	2.13	Hold	$20.40	103.82% Upside

Current Analyst Ratings Breakdown

Latest INKT, FTFT, GLSI, and KROS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2026	KROS Keros Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/21/2026	GLSI Greenwich LifeSciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $69.00
7/14/2026	INKT MiNK Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/6/2026	INKT MiNK Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/24/2026	FTFT Future FinTech Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/17/2026	INKT MiNK Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/27/2026	INKT MiNK Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/18/2026	INKT MiNK Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00
5/15/2026	GLSI Greenwich LifeSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
5/15/2026	KROS Keros Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
5/12/2026	INKT MiNK Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FTFT Future FinTech Group	$3.83M	0.45	N/A	N/A	$34.83 per share	0.03
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.03 per share	N/A
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	($3.03) per share	N/A
KROS Keros Therapeutics	$33.18M	5.97	$4.51 per share	2.22	$15.51 per share	0.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FTFT Future FinTech Group	-$4.62M	-$12.68	N/A	N/A	N/A	-37.76%	-13.08%	-10.33%	N/A
GLSI Greenwich LifeSciences	-$19.36M	-$1.57	N/A	N/A	N/A	N/A	-941.15%	-368.53%	8/13/2026 (Estimated)
INKT MiNK Therapeutics	-$12.49M	-$2.84	N/A	N/A	N/A	N/A	N/A	-118.57%	8/13/2026 (Estimated)
KROS Keros Therapeutics	$87.01M	-$3.01	N/A	N/A	N/A	-256.60%	-17.04%	-15.84%	8/5/2026 (Estimated)

Latest INKT, FTFT, GLSI, and KROS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	GLSI Greenwich LifeSciences	-$0.33	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	INKT MiNK Therapeutics	-$0.60	N/A	N/A	N/A	N/A	N/A
8/5/2026	Q2 2026	KROS Keros Therapeutics	-$1.25	N/A	N/A	N/A	$0.81 million	N/A
5/15/2026	Q1 2026	FTFT Future FinTech Group	N/A	-$1.00	N/A	-$0.25	N/A	$0.21 million
5/15/2026	Q1 2026	INKT MiNK Therapeutics	-$0.77	-$0.57	+$0.20	-$0.57	N/A	N/A
5/14/2026	Q1 2026	KROS Keros Therapeutics	-$1.0229	-$1.21	-$0.1871	-$1.21	$1.93 million	$0.37 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FTFT Future FinTech Group	N/A	N/A	N/A	N/A	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FTFT Future FinTech Group	N/A	6.82	6.82
GLSI Greenwich LifeSciences	N/A	2.01	2.01
INKT MiNK Therapeutics	N/A	1.38	1.38
KROS Keros Therapeutics	N/A	22.61	22.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FTFT Future FinTech Group	0.19%
GLSI Greenwich LifeSciences	4.16%
INKT MiNK Therapeutics	2.87%
KROS Keros Therapeutics	71.56%

Insider Ownership

Company	Insider Ownership
FTFT Future FinTech Group	1.50%
GLSI Greenwich LifeSciences	51.47%
INKT MiNK Therapeutics	20.40%
KROS Keros Therapeutics	12.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FTFT Future FinTech Group	70	1.87 million	1.84 million	No Data
GLSI Greenwich LifeSciences	3	14.68 million	7.12 million	Not Optionable
INKT MiNK Therapeutics	30	4.98 million	3.97 million	No Data
KROS Keros Therapeutics	100	19.79 million	17.30 million	Optionable

INKT, FTFT, GLSI, and KROS Headlines

Recent News About These Companies

Arrowstreet Capital Limited Partnership Sells 744,267 Shares of Keros Therapeutics, Inc. $KROS

August 3 at 3:11 AM | marketbeat.com

Keros Therapeutics (NASDAQ:KROS) Lowered to Strong Sell Rating by Zacks Research

July 31 at 6:59 AM | marketbeat.com

Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda

July 30, 2026 | globenewswire.com

New Strong Sell Stocks for July 30th

July 30, 2026 | zacks.com

Keros Therapeutics (KROS) Projected to Post Earnings on Wednesday

July 29, 2026 | marketbeat.com

Keros Therapeutics, Inc. annonce la nomination d'Annita Tanini au poste de responsable comptable par intérim, à compter du 4 août 2026

July 24, 2026 | zonebourse.comZ

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Hold" by Brokerages

July 16, 2026 | marketbeat.com

Keros Therapeutics’ TROPOS Trial Termination: What It Means for KROS Investors

July 2, 2026 | tipranks.com

Keros Therapeutics Appoints Anne Prener to its Board of Directors

June 25, 2026 | globenewswire.com

Jean Jacques Bienaime Acquires 1,000 Shares of Keros Therapeutics (NASDAQ:KROS) Stock

June 18, 2026 | insidertrades.com

KROS Share News Today

June 14, 2026 | uk.investing.com

Keros Therapeutics (NASDAQ:KROS) Director Julius Knowles Sells 2,625 Shares

June 9, 2026 | insidertrades.com

Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 8, 2026 | seekingalpha.com

Insider Selling: Keros Therapeutics (NASDAQ:KROS) Director Sells 2,625 Shares of Stock

June 6, 2026 | insidertrades.com

Bank of America Securities Reaffirms Their Hold Rating on Keros Therapeutics (KROS)

June 5, 2026 | theglobeandmail.com

Keros Therapeutics CEO to Present at Goldman Sachs Conference

June 2, 2026 | theglobeandmail.com

Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference

June 1, 2026 | globenewswire.com

Should You Buy KROS After Q1 Miss and Takeda Deal Reset?

May 22, 2026 | zacks.com

KROS Turns to Next Wave of TGF-Beta Muscle Therapies

May 22, 2026 | zacks.com

KROS Stock Guide to Rinvatercept in DMD and ALS for 2026

May 22, 2026 | zacks.com

Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20

May 17, 2026 | uk.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INKT, FTFT, GLSI, and KROS Company Descriptions

Future FinTech Group NASDAQ:FTFT

$0.92 -0.10 (-10.24%)

As of 11:20 AM Eastern

Future FinTech Group Inc., through its subsidiaries, operates online shopping platforms in People's Republic of China. It operates in three segments: Supply Chain Financing Service and Trading Business, Asset Management Service, and Others. The company offers cross-border money transfer service, brokerage and investment banking, and cryptocurrency mining farm business. It also engages in the trading of coal, aluminum ingots, sand, and steel; and E-commerce, digital wallet safety management, blockchain code auditing and operations, cryptocurrency mining, metaverse and big data maintenance services. The company was formerly known as SkyPeople Fruit Juice, Inc. and changed its name to Future FinTech Group Inc. in June 2017. Future FinTech Group Inc. is headquartered in New York, New York.

Greenwich LifeSciences NASDAQ:GLSI

$13.35 -0.15 (-1.11%)

As of 11:55 AM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

MiNK Therapeutics NASDAQ:INKT

$10.65 +0.15 (+1.40%)

As of 11:53 AM Eastern

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Keros Therapeutics NASDAQ:KROS

$10.01 -0.06 (-0.61%)

As of 11:55 AM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INKT, FTFT, GLSI, and KROS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INKT, FTFT, GLSI, and KROS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INKT, FTFT, GLSI, and KROS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INKT, FTFT, GLSI, and KROS Company Descriptions

Future FinTech Group NASDAQ:FTFT

Greenwich LifeSciences NASDAQ:GLSI

MiNK Therapeutics NASDAQ:INKT

Keros Therapeutics NASDAQ:KROS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INKT, FTFT, GLSI, and KROS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INKT, FTFT, GLSI, and KROS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INKT, FTFT, GLSI, and KROS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INKT, FTFT, GLSI, and KROS Company Descriptions

Future FinTech Group NASDAQ:FTFT

Greenwich LifeSciences NASDAQ:GLSI

MiNK Therapeutics NASDAQ:INKT

Keros Therapeutics NASDAQ:KROS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools